Charlie Holst

Charlie Holst is an experienced biotechnology professional currently serving as Vice President and Head of Biology at Ten63 Therapeutics since April 2023. Previous roles include Senior Director of Biology at Ribometrix Inc. and PTC Therapeutics, as well as Director of Biology at BioElectron Technology Corporation and Edison Pharmaceuticals. Notably, Charlie held a Senior Principal Scientist position at Pfizer, focusing on therapeutic innovation, and provided consultancy for Pathway Therapeutics Ltd. Additional experience includes serving as Senior Scientist and Research Scientist II at Exelixis and completing a Postdoctoral Fellowship at Genentech. Charlie holds a PhD in Cancer Biology from the University of California, San Francisco, and a BA in Biology from Lawrence University.